ketotifen has been researched along with Chalazia in 1 studies
Ketotifen: A cycloheptathiophene blocker of histamine H1 receptors and release of inflammatory mediators. It has been proposed for the treatment of asthma, rhinitis, skin allergies, and anaphylaxis.
ketotifen : An organic heterotricyclic compound that is 4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one which is substituted at position 4 by a 1-methylpiperidin-4-ylidene group. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is used (usually as its hydrogen fumarate salt) for the treatment of asthma, where it may take several weeks to exert its full effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dennis, M | 1 |
| Maoz, A | 1 |
| Hughes, D | 1 |
| Sanchorawala, V | 1 |
| Sloan, JM | 1 |
| Sarosiek, S | 1 |
1 other study available for ketotifen and Chalazia
| Article | Year |
|---|---|
Bortezomib ocular toxicities: Outcomes with ketotifen.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chalazion; Con | 2019 |